头条新闻！街舞文化再燃荧屏，《了不起！舞社2》定档：多元主理人碰撞火花，街舞厂牌展现风采

街舞文化再燃荧屏，《了不起！舞社2》定档：多元主理人碰撞火花，街舞厂牌展现风采

由优酷出品的明星带队舞社竞技真人秀节目《了不起！舞社》第二季将于4月8日正式播出。今日，节目举办看片会，总导演陆伟携主理人杨丞琳、郑秀妍、高瀚宇、李斯丹妮、程潇、赞多亮相，并与高校舞社代表热情互动，共同揭秘第二季的精彩看点。

全新赛制聚焦厂牌，多元主理人碰撞火花

与第一季不同，《了不起！舞社》第二季将聚焦街舞厂牌的生存与发展，以“厂牌季”的全新赛制为核心，带领观众领略街舞文化的独特魅力。21支国内顶尖街舞厂牌将悉数登场，在齐舞对抗赛制的角逐中展现风采。

为了更好地呈现厂牌特色，节目邀请了六位风格各异的明星担任主理人。杨丞琳作为舞社事务总管兼主理人，将带领舞社征战赛场；郑秀妍的加入，则为节目增添了国际化视野；高瀚宇和李斯丹妮则凭借丰富的舞台经验和强大的精神力，为节目注入了新鲜活力；而老主理人程潇和赞多，则将继续发挥他们的经验和影响力，为节目带来更多精彩看点。

总导演陆伟：希望为街舞厂牌提供更好平台

在看片会上，总导演陆伟详细介绍了第二季的赛制和亮点。他表示，之所以选择“厂牌季”的主题，是因为近年来国内很多街舞厂牌都面临着巨大的生存压力。希望通过这个节目，能够为这些厂牌提供一个更好的平台，帮助他们重焕活力，传播街舞文化。

多元化内容传递正能量，关注年轻观众情感价值

除了精彩的竞技之外，《了不起！舞社》第二季还将传递更多正能量，关注年轻观众的情感价值。节目将通过展现舞者们刻苦训练、追逐梦想的故事，鼓励年轻人勇敢追梦，不畏挑战。

陆伟表示，希望《了不起！舞社》第二季能够成为一档兼具观赏性和正能量的节目，为观众带来欢乐和感动，同时也为街舞文化的推广和发展贡献力量。

全新阵容，全新赛制，全新看点，《了不起！舞社》第二季即将燃情开播，敬请期待！

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.